Clinical Trial Update: Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2 [Phase 3]

View source ↗

Summary

Phase 3 trial (DEFEND-2) evaluating otelixizumab in adolescents and adults with newly diagnosed type 1 diabetes completed with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Otelixizumab (otelixizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2017-09-15